

MARPAI, INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS

22% INCREASE IN REVENUE IN Q3 2021 VERSUS THE SECOND QUARTER OF 2021

COMPANY PROVIDES 2021 FOURTH QUARTER REVENUE GUIDANCE OF \$5.6M-\$5.8M

NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (NASDAQ: MRAI), a deep learning technology company transforming third party administration (TPA) in the self-funded health insurance market, today reported financial results for the quarter and nine months ended September 30, 2021.



The Company's consolidated results of operations include the results of operations of Marpai and its wholly owned subsidiary Marpai Health, Inc. for all periods presented and the results of Continental Benefits, LLC. since its acquisition on April 1, 2021.

Financial Highlights

- Net revenue of approximately \$4.8 million for the third quarter of 2021, compared to revenues of approximately \$3.5 million for the first six months of 2021 (which included the revenues of Continental Benefits for the period April 1, 2021 through June 30, 2021), representing a sequential increase of approximately 36%. The Company's revenues for the third quarter of 2020 were zero as prior to the acquisition of Continental Benefit it did not have any revenues.
- Excluding purchase price related accounting adjustment to revenues of approximately \$400,000, net revenue for the three months ended June 30, 2021 were approximately \$3.9 million, which results in Q3 2021 sequential revenue growth of approximately 22%.
- The number of our customers' employees covered under the Company's administered health plans increased by approximately 23% from 20,400 on June 30, 2021 to 25,136 on September 30, 2021.
- Operating expenses were approximately \$9.5 million for the third quarter of 2021 as compared to approximately \$0.8 million for the third quarter of 2020, reflecting the acquisition of Continental Benefit and the increase in the overall level of activity in the Company.
- Net loss was approximately \$4.8 million for the third quarter of 2021 as compared to net loss of approximately \$0.9 million for the third quarter of 2020.
- Adjusted negative EBITDA of approximately \$3.7 million for the third guarter 2021

- compared to negative EBITDA of approximately \$0.6 million for the third quarter of 2020.
- On October 29, 2021, the Company closed its initial public offering (IPO), and issued 7,187,500 shares of common stock (including the exercise and closing of the underwriters' over-allotment option shares) at a price of \$4 per share with gross proceeds of \$28.75 million and net proceeds of approximately \$24.8 million, after deducting underwriting commissions and offering expenses.

"I am very pleased with our third quarter revenue growth," said Edmundo, Gonzalez, Chief Executive Officer. "We are laser focused on bringing our Artificial Intelligence-powered services to market, allowing our self-funded clients to have a valuable alternative to traditional third-party administrators. Our successful IPO has provided us with the financial strength to accelerate these growth strategies. We are grateful for the support of our new and legacy investors, and I am very excited about the potential of Marpai moving forward."

Q4 2021 Financial Guidance

The Company expects fourth quarter 2021 revenue to be in a range of \$5.6 million to \$5.8 million, representing sequential growth of 17% to 21% compared to the third quarter of 2021.

The foregoing forward-looking statements reflect our expectations as of today's date. Given the number of risk factors, uncertainties and assumptions discussed below, actual results may differ materially. We do not intend to update our financial outlook until our next quarterly results announcement.

Webcast and Conference Call Information

Marpai will host a conference call and webcast today, Thursday, December 9 at 4:15 p.m. ET to answer questions about the Company's operational and financial highlights for its third quarter ended September 30, 2021.

Investors interested in listening to the conference call may do so by dialing (844)-407-9716 for domestic callers or +1-201-493-6779 for international callers, or via webcast: https://viavid.webcasts.com/starthere.jsp?ei=1517026&tp_key=d15f900a41.

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until December 23, 2021 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13725448. A recording of the webcast will also be available for 90 days on the Marpai, Inc. investor relations site https://ir.marpaihealth.com.

About Marpai, Inc.

Marpai, Inc. (Nasdaq: MRAI) is a technology company delivering an AI-powered alternative to traditional TPAs (third party administrators) in the self-funded health plan sector representing over \$1T in annual healthcare claims and 95 million Americans. Marpai uses advanced technologies, including proprietary predictive deep learning models, to drive healthcare costs down and health outcomes up. Marpai's SMART services system predicts member health states to prevent costly events, elevates care quality, rigorously processes claims and empowers members to live healthier lives. Marpai serves self-funded employers nationwide, offers world class provider networks including Aetna and Cigna, and partners

with brokers and consultants across the country. For more information, visit www.marpaihealth.com.

Forward-Looking Statement Disclaimer

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding anticipated fourth-quarter results. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.

Media contact:
Karen Blondell
Lightspeed PR
karen@lightspeedpr.com
424-263-7371

Investor Relations contact:
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
or 407-491-4498
dave@redchip.com

Use of Non-GAAP Financial Measures and Their Limitations

In addition to our results and measures of performance determined in accordance with U.S. GAAP presented in this press release, we believe that certain non-GAAP financial measures are useful in evaluating and comparing our financial and operational performance over multiple periods, identifying trends affecting our business, formulating business plans and making strategic decisions.

Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal planning and forecasting purposes.

We believe that Adjusted EBITDA, together with a reconciliation to net income, helps identify

underlying trends in our business and helps investors make comparisons between our company and other companies that may have different capital structures, tax rates, or different forms of employee compensation. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to a key financial metric used by our management in its financial and operational decision-making. Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider these measures in isolation or as a substitute for analysis of our financial results as reported under U.S. GAAP. Some of these potential limitations include:

- other companies, including companies in our industry which have similar business arrangements, may report Adjusted EBITDA, or similarly titled measures but calculate them differently, which reduces their usefulness as comparative measures;
- although depreciation and amortization expenses are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditures for such replacements or for new capital expenditure requirements;
- Adjusted EBITDA also does not reflect changes in, or cash requirements for, our working capital needs or the potentially dilutive impact of stock-based compensation; and
- Adjusted EBITDA does not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt that we may incur.

Because of these and other limitations, you should consider our non-GAAP measures only as supplemental to other GAAP-based financial measures

MARPAI, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) (unaudited)

	September 30, 2021	December 31, 2020
ASSETS		
Current assets:	_	_
	\$	\$
Cash and cash equivalents	1,191	1,755
Restricted cash	7,810	63
Accounts receivable Unbilled, receivable	300 38	-
Prepaid expenses and other current assets	774	262
Other current assets	53	100
Total current assets	10,166	2,180
rotal current assets	10,100	2,100
Property and equipment, net	721	195
Capitalized software, net	6,617	3,819
Operating lease right-of-use assets		
Goodwill	1,547 1,676	337
Intangible assets, net	6,503	-
Security deposits	52	-
Cooling deposits	\$	\$
Total assets	27,282	6,532
Total about		3,332
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
Current liabilities:		
	\$	\$
Accounts payable	2,651	159
Accounts payable - related party	-	16
Accrued expenses	1,933	268
Accrued fiduciary obligations	5,064	-
Deferred revenues Current parties of apprating loose obligations	1,352 714	- 96
Current portion of operating lease obligations Current portion of convertible notes payable	999	1,866
Short-term loan	2,011	1,000
Due to related party	2,011	244
Total current liabilities	14,728	2,649
1541.541.141	,. 20	2,010
Convertible notes payable, net of current portion	4,866	7,096
Other long-term liabilities	45	-
Operating lease liabilities, net of current portion	1,027	283
Deferred tax liabilities	2,001	
Total liabilities	22,667	10,028
Commitments and contingencies		
STOCKHOLDERS' EQUITY (DEFICIT)		
Common stock, \$0.0001 par value, 227,791,050 shares authorized; 11,169,825 issued and outstanding		
at September 30, 2021 and 142,369 issued and outstanding as of December 31, 2020 (1)	1	1
Additional paid-in-capital	20.411	2,044
Accumulated deficit	(15,797)	(5,541)
Total stockholders' equity (deficit)	4,615	(3,496)
and the state of t	\$	\$
Total liabilities & stockholders' equity (deficit)	27,282	6,532
rotal habilities a stockholders equity (deficit)	,	,

(1) Reflects 4.55821-for-1 forward split that became effective September 2, 2021.

MARPAI, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data) (unaudited)

	Three Mont Septeml 2021		Nine Months Ended September 30, 2021 2020		
	\$	\$	\$	\$	
Revenue	4,799	-	8,331	-	
Costs and Expenses					
Cost of revenue (exclusive of depreciation and amortization shown					
separately below)	3,343	-	6,064	-	
General and administrative	2,230	281	5,045	1,054	
Sales and marketing	1,589	22	3,033	28	
Information technology	770	-	1,501	-	
Research and development	569	471	1,118	1,497	
Depreciation and amortization	802	18	1,223	56	
Facilities	232		459	-	
Total costs and expenses	9,535	792	18,443	2,635	
Operating Loss	(4,736)	(792)	(10,112)	(2,635)	
Other income (expenses)					
Other income	55	6	109	19	
Interest expense	(109)	(138)	(385)	(364)	
Foreign exchange loss	(3)	(3)	(19)	(5)	
(Loss) before provision for income taxes	(4,793)	(926)	(10,406)	(2,985)	
Income tax benefit	-	-	(150)	-	
	\$	\$	\$	\$	
Net loss	(4,793)	(926)	(10,256)	(2,985)	
	\$	\$	\$	\$	
Net loss per share, basic & fully diluted (1)	(0.47)	(0.37)	(1.31)	(1.29)	
Weighted average number of common shares, basic and fully diluted (1)	10,261,001	2,521,010	7,846,348	2,315,544	

⁽¹⁾ Reflects 4.55821-for-1 forward split that became effective September 2, 2021. The computation of basis and diluted net loss per share was retroactively adjusted for all periods presented.

MARPAI, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited)

		Nine Months Ended September 30, 2021 2020		
Cash flows from operating activities:	2021	2020		
caon no no morpotating activities	\$	\$		
Net loss	(10,256)	(2,985)		
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation and amortization	1,223	56		
Share-based compensation	962	836		
Amortization of right-to-use asset	43	58		
Amortization of debt discount	27	75		
Non-cash interest	352	286		
Convertible note issued for professional services Deferred taxes	75 (150)	-		
Changes in operating assets and liabilities:	(150)	-		
(Increase) in accounts receivable and unbilled receivables	(245)	_		
(Increase) in prepaid expenses and other assets	(380)	(106)		
Decrease in other receivables	47	(100)		
Decrease in security deposits	3	_		
Increase in accounts payable	1,566	70		
(Decrease) increase in accounts payable-related party	(16)	16		
Increase in accrued expenses	397	113		
Increase in accrued fiduciary obligations	993	-		
(Decrease) in operating lease liabilities	(74)	(65)		
(Decrease) in due to related party	(240)	-		
Increase in other liabilities	147			
Net cash used in operating activities	(5,526)	(1,646)		
Cash flows from investing activities				
Cash and restricted cash acquired as part of the acquisition of Continental Benefits	11,384	-		
Capitalization of software development costs	(1,212)	(140)		
Purchase of property and equipment	(67)	(32)		
Reimbursement of leasehold improvements from lease	40.405	46		
Net cash provided by (used in) investing activities	10,105	(126)		
Cash flows from financing activities				
Proceeds from stock options exercised	1	-		
Proceeds from convertible notes	550	2,000		
Proceeds from short-term loan	2,000			
Proceeds from issuance of warrants	53			
Net cash provided by financing activities	2,604	2,000		
Net increase in cash, cash equivalents and restricted cash	7,183	227		
Cash, cash equivalents and restricted cash at beginning of the period	1,818	246		
	\$	\$		
Cash, cash equivalents and restricted cash at end of period	9,001	474		
Reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheet				
	\$	\$		
Cash and cash equivalents	1,191	414		
Restricted cash	7,810	59		
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows	\$ 9,001	\$ 474		
	0,001			
Supplemental disclosures of non-cash activity	\$	\$		
Conversion of convertible notes at the closing of the Continental Benefits acquisition	4,175	-		
• • • • • • • • • • • • • • • • • • • •	\$	\$		
Common stock issued as part of the acquisition of Continental Benefits	8,500	-		
	-,			

MARPAI, INC. AND SUBSIDIARIES RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA (in thousands) (unaudited)

	Three Months Ended September 30,		Nine Months Ended September 31,				
		2021	 2020		2021		2020
Net Income (loss)	\$	(4,793)	\$ (926)	\$	(10,256)	\$	(2,985)
Interest expense and foreign exchange loss, net		57	135		295		350
Income tax (benefit)		-	-		(150)		-
Depreciation and amortization expense		802	18		1,223		56
Stock based compensation expense		253	195		962		836
Adjusted EBITDA	\$	(3,681)	\$ (578)	\$	(7,926)	\$	(1,743)

C View original content to download multimedia https://www.prnewswire.com/news-releases/marpai-inc--reports-third-quarter-2021-financial-results-301441690.html

SOURCE Marpai Health